Menopause

HONOLULU – Women with greater ovarian reserve had lower cardiovascular risk in a prospective study of 1,092 healthy, ovulating women aged 25-45 years, 250 of whom were followed for 3-5 years.

Measures of ovarian aging at baseline were inversely correlated with measures of systemic cellular aging. At the follow-up assessment, women who’d had lower ovarian reserve at baseline were more likely to have higher Framingham Heart Study assessment scores predicting increased risk for cardiovascular events.

“The ovary may be particularly sensitive to cellular aging” and could provide a relatively simple, objective way to identify long-term cardiovascular risk earlier in some women, Dr. Marcelle I. Cedars said at the annual meeting of the American Society for Reproductive Medicine.

She and her associates tested the women for anti-Müllerian hormone levels (AMH) and antral follicle counts (AFC) as markers of ovarian reserve. They assessed cellular aging by examining telomere length and mitochondrial DNA copy numbers in circulating white blood cells as biomarkers of cellular senescence. Shorter telomere length has been associated with worse cardiovascular risk in previous studies, she noted. The current study also measured lipid levels, fasting glucose, insulin levels, body mass index, waist circumference, and blood pressure.

Sherry Boschert/Frontline Medical Media

Women with higher AFC and AMH at baseline had healthier lipid profiles at follow-up 3-5 years later, reported Dr. Cedars, director of the division of reproductive endocrinology and of the Center for Reproductive Health at the University of California, San Francisco. The upper 10th percentile of AFC levels were associated with significantly longer telomeres and significantly lower numbers of mitochondrial DNA copies, compared with the lowest 10th percentile of AFC.

Women with higher AFC or AMH at baseline had significantly lower Framingham risk scores at follow-up, compared with women with low AFC or average AFC, she said. The Framingham scores at follow-up showed a 10-year risk of MI of 2.1% in women in the low AFC tertiles, 1.3% in women in middle AFC tertiles, and 1.1% in women in high AFC tertiles.

The difference in cardiovascular risk level was statistically significant between the high and low tertiles for AFC and between the middle and low tertiles for AFC. For AMH levels, the difference in cardiovascular risk was significant between high and low tertiles, between high and middle tertiles, and between middle and low tertiles.

The ovary’s sensitivity to oxidative stress and telomere shortening plus the need for functional mitochondrial DNA in the oocyte may underlie the process that makes ovarian age a potential window onto cardiovascular risk, the investigators hypothesized.

Previous studies have shown that women with cardiovascular disease tend to be diagnosed later and generally to have a worse prognosis, compared with men, Dr. Cedars said. Using ovarian “age” as a window onto cardiovascular risk might help close that gap, she suggested.

Dr. Cedars reported financial associations with Nora Therapeutics, Ferring Pharmaceuticals, and the founders of Telome Health, a company that measures telomere length.

[email protected]

On Twitter @sherryboschert

HONOLULU – Women with greater ovarian reserve had lower cardiovascular risk in a prospective study of 1,092 healthy, ovulating women aged 25-45 years, 250 of whom were followed for 3-5 years.

Measures of ovarian aging at baseline were inversely correlated with measures of systemic cellular aging. At the follow-up assessment, women who’d had lower ovarian reserve at baseline were more likely to have higher Framingham Heart Study assessment scores predicting increased risk for cardiovascular events.

“The ovary may be particularly sensitive to cellular aging” and could provide a relatively simple, objective way to identify long-term cardiovascular risk earlier in some women, Dr. Marcelle I. Cedars said at the annual meeting of the American Society for Reproductive Medicine.

She and her associates tested the women for anti-Müllerian hormone levels (AMH) and antral follicle counts (AFC) as markers of ovarian reserve. They assessed cellular aging by examining telomere length and mitochondrial DNA copy numbers in circulating white blood cells as biomarkers of cellular senescence. Shorter telomere length has been associated with worse cardiovascular risk in previous studies, she noted. The current study also measured lipid levels, fasting glucose, insulin levels, body mass index, waist circumference, and blood pressure.

Sherry Boschert/Frontline Medical Media

Women with higher AFC and AMH at baseline had healthier lipid profiles at follow-up 3-5 years later, reported Dr. Cedars, director of the division of reproductive endocrinology and of the Center for Reproductive Health at the University of California, San Francisco. The upper 10th percentile of AFC levels were associated with significantly longer telomeres and significantly lower numbers of mitochondrial DNA copies, compared with the lowest 10th percentile of AFC.

Women with higher AFC or AMH at baseline had significantly lower Framingham risk scores at follow-up, compared with women with low AFC or average AFC, she said. The Framingham scores at follow-up showed a 10-year risk of MI of 2.1% in women in the low AFC tertiles, 1.3% in women in middle AFC tertiles, and 1.1% in women in high AFC tertiles.

The difference in cardiovascular risk level was statistically significant between the high and low tertiles for AFC and between the middle and low tertiles for AFC. For AMH levels, the difference in cardiovascular risk was significant between high and low tertiles, between high and middle tertiles, and between middle and low tertiles.

The ovary’s sensitivity to oxidative stress and telomere shortening plus the need for functional mitochondrial DNA in the oocyte may underlie the process that makes ovarian age a potential window onto cardiovascular risk, the investigators hypothesized.

Previous studies have shown that women with cardiovascular disease tend to be diagnosed later and generally to have a worse prognosis, compared with men, Dr. Cedars said. Using ovarian “age” as a window onto cardiovascular risk might help close that gap, she suggested.

Dr. Cedars reported financial associations with Nora Therapeutics, Ferring Pharmaceuticals, and the founders of Telome Health, a company that measures telomere length.

[email protected]

On Twitter @sherryboschert

HONOLULU – Women with greater ovarian reserve had lower cardiovascular risk in a prospective study of 1,092 healthy, ovulating women aged 25-45 years, 250 of whom were followed for 3-5 years.

Measures of ovarian aging at baseline were inversely correlated with measures of systemic cellular aging. At the follow-up assessment, women who’d had lower ovarian reserve at baseline were more likely to have higher Framingham Heart Study assessment scores predicting increased risk for cardiovascular events.

“The ovary may be particularly sensitive to cellular aging” and could provide a relatively simple, objective way to identify long-term cardiovascular risk earlier in some women, Dr. Marcelle I. Cedars said at the annual meeting of the American Society for Reproductive Medicine.

She and her associates tested the women for anti-Müllerian hormone levels (AMH) and antral follicle counts (AFC) as markers of ovarian reserve. They assessed cellular aging by examining telomere length and mitochondrial DNA copy numbers in circulating white blood cells as biomarkers of cellular senescence. Shorter telomere length has been associated with worse cardiovascular risk in previous studies, she noted. The current study also measured lipid levels, fasting glucose, insulin levels, body mass index, waist circumference, and blood pressure.

Sherry Boschert/Frontline Medical Media

Women with higher AFC and AMH at baseline had healthier lipid profiles at follow-up 3-5 years later, reported Dr. Cedars, director of the division of reproductive endocrinology and of the Center for Reproductive Health at the University of California, San Francisco. The upper 10th percentile of AFC levels were associated with significantly longer telomeres and significantly lower numbers of mitochondrial DNA copies, compared with the lowest 10th percentile of AFC.

Women with higher AFC or AMH at baseline had significantly lower Framingham risk scores at follow-up, compared with women with low AFC or average AFC, she said. The Framingham scores at follow-up showed a 10-year risk of MI of 2.1% in women in the low AFC tertiles, 1.3% in women in middle AFC tertiles, and 1.1% in women in high AFC tertiles.

The difference in cardiovascular risk level was statistically significant between the high and low tertiles for AFC and between the middle and low tertiles for AFC. For AMH levels, the difference in cardiovascular risk was significant between high and low tertiles, between high and middle tertiles, and between middle and low tertiles.

The ovary’s sensitivity to oxidative stress and telomere shortening plus the need for functional mitochondrial DNA in the oocyte may underlie the process that makes ovarian age a potential window onto cardiovascular risk, the investigators hypothesized.

Previous studies have shown that women with cardiovascular disease tend to be diagnosed later and generally to have a worse prognosis, compared with men, Dr. Cedars said. Using ovarian “age” as a window onto cardiovascular risk might help close that gap, she suggested.

Dr. Cedars reported financial associations with Nora Therapeutics, Ferring Pharmaceuticals, and the founders of Telome Health, a company that measures telomere length.

[email protected]

On Twitter @sherryboschert

NATIONAL HARBOR, MD. – Relizen, a nonhormonal purified pollen extract with demonstrated efficacy in treating vasomotor symptoms of menopause, had negligible effects on the CYP2D6 enzyme at five times the recommended daily dose, according to a poster presentation.

Because tamoxifen is metabolized into endoxifen, the active metabolite in the CYP2D6 enzyme, the findings could mean women with severe hot flashes who are taking tamoxifen now have a viable treatment option that won’t increase their risk of death from breast cancer.

“Tamoxifen creates some of the worst hot flashes we will ever see,” Dr. Steven R. Goldstein, professor of obstetrics and gynecology at New York University, said in an interview at this year’s annual meeting of the North American Menopause Society. Even so, because systemic estrogen is contraindicated in women using either tamoxifen or raloxifene for the treatment or chemoprevention of breast cancer, and questions remain about the safety of phytoestrogens, many of these women forgo the commonly prescribed estrogen-based treatments for menopausal symptoms.

Instead, some physicians will prescribe off-label low doses of antidepressants to treat vasomotor symptoms in this patient population. However, a 2010 population-based cohort study of 2,430 Canadian women taking tamoxifen concurrently with an SSRI showed that the risk of death from breast cancer increased 24%-91% in those taking paroxetine in particular, depending on the increasing overlap of tamoxifen treatment and antidepressant use (BMJ 2010;340:c693 [doi:10.1136/bmj.c693]). Last year, the Food and Drug Administration approved the vasomotor symptoms of menopause as an indication for the SSRI paroxetine (Paxil, Brisdelle), but required Noven, the drug’s manufacturer, to state paroxetine’s countering effect on tamoxifen’s efficacy.

Until now, according to Dr. Goldstein, fears over estrogen and SSRI’s potential ill-effects have meant that many women have chosen to “tough it out” when it comes to hot flashes, night sweats, and other symptoms.

The importance of his study, he said, is that because Relizen (Sérélyspharma, France), a powdered, pollen cytoplasmic extract harvested in southern Sweden, doesn’t affect the CYP enzyme system, it’s safe to give to tamoxifen patients. “It is the only nonpharmacologic product that I have ever been aware of that has a double-blind, randomized, placebo-controlled, parallel study showing that it reduces vasomotor symptoms and improves quality of life in menopausal women,” Dr. Goldstein said.

In an in vitro study of Relizen’s effect on the isoenzyme CYP2D6 in pooled human liver microsomes, Dr. Goldstein and his colleagues tested the supplement against quinidine, a known CYP2D6 inhibitor. The end point was the conversion of bufuralol to 1-OH-bufuralol in the CYP enzyme system. Six concentrations of each compound were tested, with all reactions being performed in triplicate. The Relizen concentrations ranged from 1.65 mcg/mL to 400 mcg/mL, five times the Relizen recommended daily dose of 80 mcg/mL. The quinidine concentrations ranged from 2.06 nM to 500 nM.

The study compound’s inhibition of CYP2D6 was negligible, ranging from –6.53% to 10.67%, compared with quinidine’s CYP2D6 linear dose-related increase from –7.07% at 2.06 nM to 84.05% at 500 nM.

Relizen’s apparent clinical utility in women at high risk of death from breast cancer is the “low-hanging fruit,” Dr. Goldstein said. “The tamoxifen patient has no other place to go. But if a woman is 51 years old and she comes to me and says she has hot flashes, now I have multiple options. I can give her hormones, I can give her 7.5 mg of paroxetine, or I can give her Relizen. This is just another arrow in my quiver.”

In the placebo-controlled study of Relizen, 65% of the active treatment group of 32 peri- and postmenopausal women reported decreased vasomotor symptoms by the end of the 12 week trial, compared with 38% of the placebo group (Climacteric 2005; 8:162-70).

“I know [Relizen] is effective, and it’s tested against placebo,” Dr. Goldstein said. “But is it as strong as estrogen? I have no clue. A head-to-head trial is not going to happen.”

Relizen has been widely available in Europe under a variety of names, including Femal, since 1999, and has had no reported adverse effects, according to the manufacturer. JDS Pharmaceuticals (Noven) began distributing the supplement in the United States earlier this year.

Dr. Goldstein is a paid consultant for JDS Pharmaceuticals, a division of Noven. The study was sponsored by the supplement manufacturer, Sérélyspharma(France). JDS Pharmaceuticals (Noven) is the licensed distributor of Relizen in the United States.

[email protected]

On Twitter @whitneymcknight

NATIONAL HARBOR, MD. – Relizen, a nonhormonal purified pollen extract with demonstrated efficacy in treating vasomotor symptoms of menopause, had negligible effects on the CYP2D6 enzyme at five times the recommended daily dose, according to a poster presentation.

Because tamoxifen is metabolized into endoxifen, the active metabolite in the CYP2D6 enzyme, the findings could mean women with severe hot flashes who are taking tamoxifen now have a viable treatment option that won’t increase their risk of death from breast cancer.

“Tamoxifen creates some of the worst hot flashes we will ever see,” Dr. Steven R. Goldstein, professor of obstetrics and gynecology at New York University, said in an interview at this year’s annual meeting of the North American Menopause Society. Even so, because systemic estrogen is contraindicated in women using either tamoxifen or raloxifene for the treatment or chemoprevention of breast cancer, and questions remain about the safety of phytoestrogens, many of these women forgo the commonly prescribed estrogen-based treatments for menopausal symptoms.

Instead, some physicians will prescribe off-label low doses of antidepressants to treat vasomotor symptoms in this patient population. However, a 2010 population-based cohort study of 2,430 Canadian women taking tamoxifen concurrently with an SSRI showed that the risk of death from breast cancer increased 24%-91% in those taking paroxetine in particular, depending on the increasing overlap of tamoxifen treatment and antidepressant use (BMJ 2010;340:c693 [doi:10.1136/bmj.c693]). Last year, the Food and Drug Administration approved the vasomotor symptoms of menopause as an indication for the SSRI paroxetine (Paxil, Brisdelle), but required Noven, the drug’s manufacturer, to state paroxetine’s countering effect on tamoxifen’s efficacy.

Until now, according to Dr. Goldstein, fears over estrogen and SSRI’s potential ill-effects have meant that many women have chosen to “tough it out” when it comes to hot flashes, night sweats, and other symptoms.

The importance of his study, he said, is that because Relizen (Sérélyspharma, France), a powdered, pollen cytoplasmic extract harvested in southern Sweden, doesn’t affect the CYP enzyme system, it’s safe to give to tamoxifen patients. “It is the only nonpharmacologic product that I have ever been aware of that has a double-blind, randomized, placebo-controlled, parallel study showing that it reduces vasomotor symptoms and improves quality of life in menopausal women,” Dr. Goldstein said.

In an in vitro study of Relizen’s effect on the isoenzyme CYP2D6 in pooled human liver microsomes, Dr. Goldstein and his colleagues tested the supplement against quinidine, a known CYP2D6 inhibitor. The end point was the conversion of bufuralol to 1-OH-bufuralol in the CYP enzyme system. Six concentrations of each compound were tested, with all reactions being performed in triplicate. The Relizen concentrations ranged from 1.65 mcg/mL to 400 mcg/mL, five times the Relizen recommended daily dose of 80 mcg/mL. The quinidine concentrations ranged from 2.06 nM to 500 nM.

The study compound’s inhibition of CYP2D6 was negligible, ranging from –6.53% to 10.67%, compared with quinidine’s CYP2D6 linear dose-related increase from –7.07% at 2.06 nM to 84.05% at 500 nM.

Relizen’s apparent clinical utility in women at high risk of death from breast cancer is the “low-hanging fruit,” Dr. Goldstein said. “The tamoxifen patient has no other place to go. But if a woman is 51 years old and she comes to me and says she has hot flashes, now I have multiple options. I can give her hormones, I can give her 7.5 mg of paroxetine, or I can give her Relizen. This is just another arrow in my quiver.”

In the placebo-controlled study of Relizen, 65% of the active treatment group of 32 peri- and postmenopausal women reported decreased vasomotor symptoms by the end of the 12 week trial, compared with 38% of the placebo group (Climacteric 2005; 8:162-70).

“I know [Relizen] is effective, and it’s tested against placebo,” Dr. Goldstein said. “But is it as strong as estrogen? I have no clue. A head-to-head trial is not going to happen.”

Relizen has been widely available in Europe under a variety of names, including Femal, since 1999, and has had no reported adverse effects, according to the manufacturer. JDS Pharmaceuticals (Noven) began distributing the supplement in the United States earlier this year.

Dr. Goldstein is a paid consultant for JDS Pharmaceuticals, a division of Noven. The study was sponsored by the supplement manufacturer, Sérélyspharma(France). JDS Pharmaceuticals (Noven) is the licensed distributor of Relizen in the United States.

[email protected]

On Twitter @whitneymcknight

NATIONAL HARBOR, MD. – Relizen, a nonhormonal purified pollen extract with demonstrated efficacy in treating vasomotor symptoms of menopause, had negligible effects on the CYP2D6 enzyme at five times the recommended daily dose, according to a poster presentation.

Because tamoxifen is metabolized into endoxifen, the active metabolite in the CYP2D6 enzyme, the findings could mean women with severe hot flashes who are taking tamoxifen now have a viable treatment option that won’t increase their risk of death from breast cancer.

“Tamoxifen creates some of the worst hot flashes we will ever see,” Dr. Steven R. Goldstein, professor of obstetrics and gynecology at New York University, said in an interview at this year’s annual meeting of the North American Menopause Society. Even so, because systemic estrogen is contraindicated in women using either tamoxifen or raloxifene for the treatment or chemoprevention of breast cancer, and questions remain about the safety of phytoestrogens, many of these women forgo the commonly prescribed estrogen-based treatments for menopausal symptoms.

Instead, some physicians will prescribe off-label low doses of antidepressants to treat vasomotor symptoms in this patient population. However, a 2010 population-based cohort study of 2,430 Canadian women taking tamoxifen concurrently with an SSRI showed that the risk of death from breast cancer increased 24%-91% in those taking paroxetine in particular, depending on the increasing overlap of tamoxifen treatment and antidepressant use (BMJ 2010;340:c693 [doi:10.1136/bmj.c693]). Last year, the Food and Drug Administration approved the vasomotor symptoms of menopause as an indication for the SSRI paroxetine (Paxil, Brisdelle), but required Noven, the drug’s manufacturer, to state paroxetine’s countering effect on tamoxifen’s efficacy.

Until now, according to Dr. Goldstein, fears over estrogen and SSRI’s potential ill-effects have meant that many women have chosen to “tough it out” when it comes to hot flashes, night sweats, and other symptoms.

The importance of his study, he said, is that because Relizen (Sérélyspharma, France), a powdered, pollen cytoplasmic extract harvested in southern Sweden, doesn’t affect the CYP enzyme system, it’s safe to give to tamoxifen patients. “It is the only nonpharmacologic product that I have ever been aware of that has a double-blind, randomized, placebo-controlled, parallel study showing that it reduces vasomotor symptoms and improves quality of life in menopausal women,” Dr. Goldstein said.

In an in vitro study of Relizen’s effect on the isoenzyme CYP2D6 in pooled human liver microsomes, Dr. Goldstein and his colleagues tested the supplement against quinidine, a known CYP2D6 inhibitor. The end point was the conversion of bufuralol to 1-OH-bufuralol in the CYP enzyme system. Six concentrations of each compound were tested, with all reactions being performed in triplicate. The Relizen concentrations ranged from 1.65 mcg/mL to 400 mcg/mL, five times the Relizen recommended daily dose of 80 mcg/mL. The quinidine concentrations ranged from 2.06 nM to 500 nM.

The study compound’s inhibition of CYP2D6 was negligible, ranging from –6.53% to 10.67%, compared with quinidine’s CYP2D6 linear dose-related increase from –7.07% at 2.06 nM to 84.05% at 500 nM.

Relizen’s apparent clinical utility in women at high risk of death from breast cancer is the “low-hanging fruit,” Dr. Goldstein said. “The tamoxifen patient has no other place to go. But if a woman is 51 years old and she comes to me and says she has hot flashes, now I have multiple options. I can give her hormones, I can give her 7.5 mg of paroxetine, or I can give her Relizen. This is just another arrow in my quiver.”

In the placebo-controlled study of Relizen, 65% of the active treatment group of 32 peri- and postmenopausal women reported decreased vasomotor symptoms by the end of the 12 week trial, compared with 38% of the placebo group (Climacteric 2005; 8:162-70).

“I know [Relizen] is effective, and it’s tested against placebo,” Dr. Goldstein said. “But is it as strong as estrogen? I have no clue. A head-to-head trial is not going to happen.”

Relizen has been widely available in Europe under a variety of names, including Femal, since 1999, and has had no reported adverse effects, according to the manufacturer. JDS Pharmaceuticals (Noven) began distributing the supplement in the United States earlier this year.

Dr. Goldstein is a paid consultant for JDS Pharmaceuticals, a division of Noven. The study was sponsored by the supplement manufacturer, Sérélyspharma(France). JDS Pharmaceuticals (Noven) is the licensed distributor of Relizen in the United States.

[email protected]

On Twitter @whitneymcknight

NATIONAL HARBOR, MD. – Menopausal women who experience vaginal dryness often find the resultant pain of sexual intercourse so prohibitive that, according to Dr. JoAnne Pinkerton, often these women go months or years without intimate relations.

There are many treatment options that can benefit patients with the condition, explained Dr. Pinkerton, medical director of the Midlife Health Center at the University of Virginia, Charlottesville, but physicians aren’t always aware of what’s available.

In a video interview at annual meeting of the North American Menopause Society, Dr. Pinkerton discussed the range of therapies physicians can offer menopausal patients with vaginal dryness.

[email protected]

On Twitter @whitneymcknight

NATIONAL HARBOR, MD. – Menopausal women who experience vaginal dryness often find the resultant pain of sexual intercourse so prohibitive that, according to Dr. JoAnne Pinkerton, often these women go months or years without intimate relations.

There are many treatment options that can benefit patients with the condition, explained Dr. Pinkerton, medical director of the Midlife Health Center at the University of Virginia, Charlottesville, but physicians aren’t always aware of what’s available.

In a video interview at annual meeting of the North American Menopause Society, Dr. Pinkerton discussed the range of therapies physicians can offer menopausal patients with vaginal dryness.

[email protected]

On Twitter @whitneymcknight

NATIONAL HARBOR, MD. – Menopausal women who experience vaginal dryness often find the resultant pain of sexual intercourse so prohibitive that, according to Dr. JoAnne Pinkerton, often these women go months or years without intimate relations.

There are many treatment options that can benefit patients with the condition, explained Dr. Pinkerton, medical director of the Midlife Health Center at the University of Virginia, Charlottesville, but physicians aren’t always aware of what’s available.

In a video interview at annual meeting of the North American Menopause Society, Dr. Pinkerton discussed the range of therapies physicians can offer menopausal patients with vaginal dryness.

[email protected]

On Twitter @whitneymcknight

NATIONAL HARBOR, MD. – Menopause is often accompanied by complex changes in sexual health and function, and factors contributing to low libido and other sexual problems in postmenopausal women may include a combination of hormonal and psychological components, according to experts at the annual meeting of the North American Menopause Society (NAMS).

In this roundtable discussion, Dr. Jan L. Shifren of Harvard Medical School, Boston; NAMS executive director Dr. Margery Gass of Cleveland Clinic; and psychologist Sheryl A. Kingsberg, Ph.D., of the Case Western Reserve University, Cleveland, discuss the physiological, psychological, and relationship factors that affect sexual function and desire in postmenopausal women.

They also talk about treatments such as psychotherapy, low-dose estrogen therapy, and testosterone therapy that may be used to address postmenopausal sexual problems, and how to determine when psychological intervention alone is adequate, and when pharmacologic intervention may be needed.

But the most important thing, they stressed, was to ask women if they are having any changes in sexual health. This is not a topic most women are likely to bring up themselves.

Dr. Kingsberg disclosed relationships with Apricus Biosciences, Emotional Brain, Metagenics, Novo Nordisk, Palatin Technologies, Pfizer, Shionogi, Sprout Pharmaceuticals, Strategic Science and Technologies, and Teva Pharmaceuticals. Dr. Gass and Dr. Shifren did not report any relevant financial disclosures.

NATIONAL HARBOR, MD. – Menopause is often accompanied by complex changes in sexual health and function, and factors contributing to low libido and other sexual problems in postmenopausal women may include a combination of hormonal and psychological components, according to experts at the annual meeting of the North American Menopause Society (NAMS).

In this roundtable discussion, Dr. Jan L. Shifren of Harvard Medical School, Boston; NAMS executive director Dr. Margery Gass of Cleveland Clinic; and psychologist Sheryl A. Kingsberg, Ph.D., of the Case Western Reserve University, Cleveland, discuss the physiological, psychological, and relationship factors that affect sexual function and desire in postmenopausal women.

They also talk about treatments such as psychotherapy, low-dose estrogen therapy, and testosterone therapy that may be used to address postmenopausal sexual problems, and how to determine when psychological intervention alone is adequate, and when pharmacologic intervention may be needed.

But the most important thing, they stressed, was to ask women if they are having any changes in sexual health. This is not a topic most women are likely to bring up themselves.

Dr. Kingsberg disclosed relationships with Apricus Biosciences, Emotional Brain, Metagenics, Novo Nordisk, Palatin Technologies, Pfizer, Shionogi, Sprout Pharmaceuticals, Strategic Science and Technologies, and Teva Pharmaceuticals. Dr. Gass and Dr. Shifren did not report any relevant financial disclosures.

NATIONAL HARBOR, MD. – Menopause is often accompanied by complex changes in sexual health and function, and factors contributing to low libido and other sexual problems in postmenopausal women may include a combination of hormonal and psychological components, according to experts at the annual meeting of the North American Menopause Society (NAMS).

In this roundtable discussion, Dr. Jan L. Shifren of Harvard Medical School, Boston; NAMS executive director Dr. Margery Gass of Cleveland Clinic; and psychologist Sheryl A. Kingsberg, Ph.D., of the Case Western Reserve University, Cleveland, discuss the physiological, psychological, and relationship factors that affect sexual function and desire in postmenopausal women.

They also talk about treatments such as psychotherapy, low-dose estrogen therapy, and testosterone therapy that may be used to address postmenopausal sexual problems, and how to determine when psychological intervention alone is adequate, and when pharmacologic intervention may be needed.

But the most important thing, they stressed, was to ask women if they are having any changes in sexual health. This is not a topic most women are likely to bring up themselves.

Dr. Kingsberg disclosed relationships with Apricus Biosciences, Emotional Brain, Metagenics, Novo Nordisk, Palatin Technologies, Pfizer, Shionogi, Sprout Pharmaceuticals, Strategic Science and Technologies, and Teva Pharmaceuticals. Dr. Gass and Dr. Shifren did not report any relevant financial disclosures.

NATIONAL HARBOR, MD. – Does the Food and Drug Administration’s black-box warning on estrogen contribute to noncompliance – or worse, to clinicians being unwilling to prescribe estrogen treatments – leaving many women to suffer untreated menopause symptoms?

The leadership of the North American Menopause Society thinks so, and the organization has started a campaign to get the FDA to reconsider how it labels estrogen.

“We would like the label for low-dose, vaginal estrogen to better reflect the true safety and risk profile,” said Dr. JoAnn Manson, chair of this year’s NAMS scientific committee.

In a video interview, Dr. Manson discusses how the current black-box labeling may impede effective treatment, and why revised, more-nuanced estrogen labeling could improve outcomes for many women.

[email protected] 


On Twitter @whitneymcknight

NATIONAL HARBOR, MD. – Does the Food and Drug Administration’s black-box warning on estrogen contribute to noncompliance – or worse, to clinicians being unwilling to prescribe estrogen treatments – leaving many women to suffer untreated menopause symptoms?

The leadership of the North American Menopause Society thinks so, and the organization has started a campaign to get the FDA to reconsider how it labels estrogen.

“We would like the label for low-dose, vaginal estrogen to better reflect the true safety and risk profile,” said Dr. JoAnn Manson, chair of this year’s NAMS scientific committee.

In a video interview, Dr. Manson discusses how the current black-box labeling may impede effective treatment, and why revised, more-nuanced estrogen labeling could improve outcomes for many women.

[email protected] 


On Twitter @whitneymcknight

NATIONAL HARBOR, MD. – Does the Food and Drug Administration’s black-box warning on estrogen contribute to noncompliance – or worse, to clinicians being unwilling to prescribe estrogen treatments – leaving many women to suffer untreated menopause symptoms?

The leadership of the North American Menopause Society thinks so, and the organization has started a campaign to get the FDA to reconsider how it labels estrogen.

“We would like the label for low-dose, vaginal estrogen to better reflect the true safety and risk profile,” said Dr. JoAnn Manson, chair of this year’s NAMS scientific committee.

In a video interview, Dr. Manson discusses how the current black-box labeling may impede effective treatment, and why revised, more-nuanced estrogen labeling could improve outcomes for many women.

[email protected] 


On Twitter @whitneymcknight

Dr. Moore and Dr. Pinkerton focus on a new estrogen therapy: the combination conjugated estrogen and bazedoxifene (CE/BZA) for the treatment of moderate to severe hot flashes due to menopause and the prevention of menopausal osteoporosis.

Which patients can benefit most? What is CE/BZA’s safety profile? How do traditional estrogen-progestin therapies compare with CE/BZA therapy? Tune in for answers to these questions and more.

Read Cases in Menopause: Conjugated estrogen plus bazedoxifene—a new approach to estrogen therapy, from Dr. Anne Moore and Dr. JoAnn Pinkerton (October 2014).

Dr. Moore and Dr. Pinkerton focus on a new estrogen therapy: the combination conjugated estrogen and bazedoxifene (CE/BZA) for the treatment of moderate to severe hot flashes due to menopause and the prevention of menopausal osteoporosis.

Which patients can benefit most? What is CE/BZA’s safety profile? How do traditional estrogen-progestin therapies compare with CE/BZA therapy? Tune in for answers to these questions and more.

Read Cases in Menopause: Conjugated estrogen plus bazedoxifene—a new approach to estrogen therapy, from Dr. Anne Moore and Dr. JoAnn Pinkerton (October 2014).

Dr. Moore and Dr. Pinkerton focus on a new estrogen therapy: the combination conjugated estrogen and bazedoxifene (CE/BZA) for the treatment of moderate to severe hot flashes due to menopause and the prevention of menopausal osteoporosis.

Which patients can benefit most? What is CE/BZA’s safety profile? How do traditional estrogen-progestin therapies compare with CE/BZA therapy? Tune in for answers to these questions and more.

Read Cases in Menopause: Conjugated estrogen plus bazedoxifene—a new approach to estrogen therapy, from Dr. Anne Moore and Dr. JoAnn Pinkerton (October 2014).